先声药业变更资金用途 涉及三种在研产品
财中社12月23日电先声药业（02096）发布公告，宣布对其所得款项用途进行进一步变更。根据公告，截至2024年6月30日，公司自全球发售及部分行使超额配股权所得款项净额约为35.13亿元，已动用的净额约为30.51亿元，剩余未动用净额约为4.62亿元。公司董事会决定将原定用于某些在研产品的部分未动用款项重新分配至新选定的在研产品，以加速其研发进程。
具体而言，重新分配的款项包括约2.29亿元用于处于临床阶段的选定肿瘤疾病在研产品，约1.8亿元用于处于临床前阶段的创新肿瘤疾病在研产品，以及约3174万元用于其他选定的创新中枢神经系统疾病在研产品。公司认为，此次变更将有助于更有效地调拨财务资源，并符合公司及股东的整体最佳利益，同时不会对公司的运营造成重大不利影响。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10